WALTHAM, Mass., Nov. 6, 2025 – Sironax, a global clinical-stage biotechnology company dedicated to discovering and developing transformative therapies for age-related degenerative diseases, today announced the selection of three abstracts for...
Program
Molecule
Potential Indications
Discovery
Lead Optimization
Preclinical Development
Phase 1a
Phase 1b/2
Late-Stage Development
SARM1 inhibition
SIR2501
SIR-X1
CIPN, ALS & neurodegenerative diseases
Neurodegenerative diseases
RIPK1 inhibition
SIR9900
Inflammation & Immunological diseases, traumatic CNS conditions
NAMPT activation
SIR4156
Neuronal & muscular degenerative diseases & metabolic diseases
Undisclosed
SIR8752
Inflammation & Immunological diseases
Brain Delivery Module (BDM)
Therapeutic payload / BDM
Neurodegenerative diseases
Early-stage programs
SIR-X2
SIR-X3
SIR-X4
Undisclosed
Undisclosed
Undisclosed
Program
SARM1 inhibition
Molecule
SIR2501
Potential Indications
CIPN, ALS & neurodegenerative diseases
Phase
Phase 1b/2
Molecule
SIR-X1
Potential Indications
Neurodegenerative diseases
Phase
Preclinical Development
Program
RIPK1 inhibition
Molecule
SIR9900
Potential Indications
Inflammation & Immunological diseases, traumatic CNS conditions
Phase
Phase 1b/2
Program
NAMPT activation
Molecule
SIR4156
Potential Indications
Neuronal & muscular degenerative diseases & metabolic diseases
Phase
Phase 1b/2
Program
Undisclosed
Molecule
SIR8752
Potential Indications
Inflammation & Immunological diseases
Phase
Preclinical Development
Program
Brain Delivery Module (BDM)
Molecule
Therapeutic payload / BDM
Potential Indications
Neurodegenerative diseases
Phase
Lead Optimization
Program
Early-stage programs
Molecule
SIR-X2
Potential Indications
Undisclosed
Phase
Discovery
Molecule
SIR-X3
Potential Indications
Undisclosed
Phase
Discovery
Molecule
SIR-X4
Potential Indications
Undisclosed
Phase
Discovery
